The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Early (< 8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants
Open accessAbstract
BACKGROUND: Bronchopulmonary dysplasia remains a major problem in neonatal intensive care units. Persistent inflammation in the lungs is the most likely underlying pathogenesis. Corticosteroids have been used to prevent or treat bronchopulmonary dysplasia because of their potent anti-inflammatory effects. OBJECTIVES: To examine the relative benefits and adverse effects of systemic postnatal corticosteroids commenced within the first seven days of life for preterm infants at risk of developing bronchopulmonary dysplasia. SEARCH METHODS: For the 2017 update, we used the standard search strategy of Cochrane Neonatal to search the Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 1); MEDLINE via PubMed (January 2013 to 21 February 2017); Embase (January 2013 to 21 February 2017); and the Cumulative Index to Nursing and Allied Health Literature (CINAHL) (January 2013 to 21 February 2017). We also searched clinical trials databases, conference proceedings, and reference lists of retrieved articles for randomised controlled trials (RCTs) and quasi-randomised trials. SELECTION CRITERIA: For this review, we selected RCTs examining systemic postnatal corticosteroid treatment within the first seven days of life (early) in high-risk preterm infants. Most studies evaluated the use of dexamethasone, but we also included studies that assessed hydrocortisone, even when used primarily for management of hypotension. DATA COLLECTION AND ANALYSIS: We used the GRADE approach to assess the quality of evidence.We extracted and analysed data regarding clinical outcomes that included mortality, bronchopulmonary dysplasia, death or bronchopulmonary dysplasia, failure to extubate, complications during primary hospitalisation, and long-term health outcomes. MAIN RESULTS: We included 32 RCTs enrolling a total of 4395 participants. The overall risk of bias of included studies was probably low, as all were RCTs, and most trials used rigorous methods. Investigators reported significant benefits for the following outcomes overall: lower rates of failure to extubate, decreased risks of bronchopulmonary dysplasia both at 28 days of life and at 36 weeks' postmenstrual age, death or bronchopulmonary dysplasia at 28 days of life and at 36 weeks' postmenstrual age, patent ductus arteriosus, and retinopathy of prematurity (ROP), including severe ROP. Researchers found no significant differences in rates of neonatal or subsequent mortality; they noted that gastrointestinal bleeding and intestinal perforation were important adverse effects, and that risks of hyperglycaemia, hypertension, hypertrophic cardiomyopathy, and growth failure were increased. The 13 trials that reported late outcomes described several adverse neurological effects at follow-up examination, including cerebral palsy. However, study authors indicated that major neurosensory disability was not significantly increased, either overall in the eight studies for which this outcome could be determined, or in the two individual studies in which rates of cerebral palsy or abnormal neurological examination were significantly increased. Moreover, data show that rates of the combined outcomes of death or cerebral palsy, or of death or major neurosensory disability, were not significantly increased. Two-thirds of studies used dexamethasone (n = 21). Subgroup analyses by type of corticosteroid revealed that most of the beneficial and harmful effects of treatment were attributable to dexamethasone. However, as with dexamethasone, hydrocortisone was associated with reduced rates of patent ductus arteriosus, mortality, and the combined outcome of mortality or chronic lung disease, but with increased occurrence of intestinal perforation. Results showed that hydrocortisone was not associated with obvious longer-term problems.Use of the GRADE approach revealed that the quality of evidence was high for the major outcomes considered, but review authors downgraded quality one level for several outcomes (mortality at latest age, bronchopulmonary dysplasia at 36 weeks, and death or bronchopulmonary dysplasia at 36 weeks) because of weak evidence of publication bias or moderate heterogeneity (death or cerebral palsy). AUTHORS' CONCLUSIONS: Benefits of early postnatal corticosteroid treatment (≤ 7 days), particularly dexamethasone, may not outweigh adverse effects associated with this treatment. Although early corticosteroid treatment facilitates extubation and reduces risk of bronchopulmonary dysplasia and patent ductus arteriosus, it causes short-term adverse effects including gastrointestinal bleeding, intestinal perforation, hyperglycaemia, hypertension, hypertrophic cardiomyopathy, and growth failure. Long-term follow-up studies report increased risk of abnormal findings on neurological examination and increased risk of cerebral palsy. However, the methodological quality of studies examining long-term outcomes is limited in some cases: Surviving children have been assessed predomi
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Northway, W. H., Rosan, R. C., & Porter, D. Y. (1967) · New England Journal of Medicine · doi:10.1056/nejm196702162760701 · Cited by 3,013
Caffeine Therapy for Apnea of Prematurity
Schmidt, B., Roberts, R. S., Davis, P., Doyle, L. W., Barrington, K. J., Ohlsson, A., Solimano, A., & Tin, W. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054065 · Cited by 1,208
Self-citationOutcomes at School Age after Postnatal Dexamethasone Therapy for Lung Disease of Prematurity
Yeh, T. F., Lin, Y. J., Lin, H. C., Huang, C. C., Hsieh, W. S., Lin, C. H., & Tsai, C. H. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032089 · Cited by 596
A Controlled Trial of Dexamethasone in Preterm Infants at High Risk for Bronchopulmonary Dysplasia
Cummings, J. J., D'Eugenio, D. B., & Gross, S. J. (1989) · New England Journal of Medicine · doi:10.1056/nejm198906083202301 · Cited by 483
Adverse Effects of Early Dexamethasone Treatment in Extremely-Low-Birth-Weight Infants
Stark, A. R., Carlo, W. A., Tyson, J. E., Papile, L.-A., Wright, L. L., Shankaran, S., Donovan, E. F., Oh, W., Bauer, C. R., Saha, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200101113440203 · Cited by 479
Self-citationWatterberg, K. L., Gerdes, J. S., Cole, C. H., Aucott, S. W., Thilo, E. H., Mammel, M. C., Couser, R. J., Garland, J. S., Rozycki, H. J., Leach, C. L., et al. (2004) · Pediatrics · doi:10.1542/peds.2004-1159 · Cited by 432
Early Dexamethasone Therapy in Preterm Infants: A Follow-up Study
Yeh, T. F., Lin, Y. J., Huang, C. C., Chen, Y. J., Lin, C. H., Lin, H. C., Hsieh, W. S., & Lien, Y. J. (1998) · Pediatrics · doi:10.1542/peds.101.5.e7 · Cited by 418
Antenatal Glucocorticoid Treatment and Cystic Periventricular Leukomalacia in Very Premature Infants
Baud, O., Foix-L'Helias, L., Kaminski, M., Audibert, F., Jarreau, P.-H., Papiernik, E., Huon, C., Lepercq, J., Dehan, M., & Lacaze-Masmonteil, T. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910143411604 · Cited by 414
Controlled Trial of Dexamethasone in Respirator-Dependent Infants with Bronchopulmonary Dysplasia
Avery, G. B., Fletcher, A. B., Kaplan, M., & Brudno, D. S. (1985) · Pediatrics · doi:10.1542/peds.75.1.106 · Cited by 379
O'Shea, T. M., Kothadia, J. M., Klinepeter, K. L., Goldstein, D. J., Jackson, B. G., Weaver, R. G., & Dillard, I. A. R. G. (1999) · Pediatrics · doi:10.1542/peds.104.1.15 · Cited by 376
Cited by
European Consensus Guidelines on the Management of Respiratory Distress Syndrome – 2019 Update
Sweet, D. G., Carnielli, V., Greisen, G., Hallman, M., Ozek, E., te Pas, A., Plavka, R., Roehr, C. C., Saugstad, O. D., Simeoni, U., et al. (2019) · Neonatology · doi:10.1159/000499361 · Cited by 1,613
Self-citationEuropean Consensus Guidelines on the Management of Respiratory Distress Syndrome: 2022 Update
Sweet, D. G., Carnielli, V. P., Greisen, G., Hallman, M., Klebermass-Schrehof, K., Ozek, E., te Pas, A., Plavka, R., Roehr, C. C., Saugstad, O. D., et al. (2023) · Neonatology · doi:10.1159/000528914 · Cited by 704
Self-citationDiagnosis and management of bronchopulmonary dysplasia
Gilfillan, M., Bhandari, A., & Bhandari, V. (2021) · BMJ · doi:10.1136/bmj.n1974 · Cited by 311
Preoperative cardiopulmonary evaluation in specific neonatal surgery
Petroze, R. T., & Puligandla, P. S. (2019) · Seminars in Pediatric Surgery · doi:10.1053/j.sempedsurg.2019.01.002 · Cited by 17
Metadata
- Authors
- Doyle, L. W., Cheong, J. L., Ehrenkranz, R. A., & Halliday, H. L.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2017-10-24
- Volume
- 2018
- Issue
- 1
- Pages
- CD001145-CD001145
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2765280053
- Cited by
- 260
- References
- 68
- FWCI
- 18.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Early (< 8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. https://app.cochat.ai/papers/10.1002/14651858.cd001146.pub5
- The paper
- Doyle, L. W., Cheong, J. L., Ehrenkranz, R. A., & Halliday, H. L. (2017). Early (< 8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd001146.pub5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.